Pharma Deals Review, Vol 2008, No 94 (2008)

Font Size:  Small  Medium  Large

Astellas and CoMentis Enter into Deal for Novel Alzheimer's Drug

The PharmaDeals Team

Abstract


Astellas has entered into a deal to build up its CNS pipeline by licensing CoMentis’ beta-secretase inhibitor programme for Alzheimer's disease.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.